Pfizer's Bold Gambit: A Nearly Half-Billion Dollar Bet on China's Obesity Market
A New Chapter in Rare Disease Treatment: Omeros and Novo Nordisk Finalize Landmark Zaltenibart Deal
The Watchdogs Are Barking: Why Metsera's Big Deal Just Hit a Snag